Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Celldex Therapeutics, Inc.

NASDAQ: CLDX · Life Sciences · 3 alerts · CIK 744218

Share price
$28.59Close, Nov 16
Market cap
$2.25B
Shares outstanding
78.55MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Celldex Therapeutics, Inc. filings on SEC EDGAR ↗

7:09 AM ET 8-K
Clinical Trial Data

Celldex Therapeutics Clinical Trial Data

Celldex reported positive topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab in chronic spontaneous urticaria (CSU), meeting the primary and all key secondary endpoints. The data showed rapid and sustained efficacy through 24 weeks, including in patients refractory to omalizumab, with a favorable safety profile. The company plans to submit a Biologics License Application (BLA) to the FDA in 2027.

Earnings call
Sep 22, 2026, 8:00 AM ET

“The results from our two Phase 3 EMBARQ-CSU trials showed efficacy that is best-in-disease in CSU. We believe barzolvolimab is well-positioned to address large CSU populations of high unmet need—as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.”

Anthony Marucci, Co-Founder, President, and Chief Executive Officer at Celldex

“Barzolvolimab continued to show unprecedented complete response rates across the overall studies and demonstrated strong differentiation in patient populations underserved by existing therapies, including those with severe disease or angioedema, and those whose disease is refractory to omalizumab.”

Diane Young, MD, Senior Vice President and Chief Medical Officer of Celldex

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.